Stephen J Freedland1,2, Brandee L Branche1, Lauren E Howard1,3, Robert J Hamilton4, William J Aronson5,6, Martha K Terris7,8, Matthew R Cooperberg9,10, Christopher L Amling11, Christopher J Kane12. 1. Division of Urology, Veterans Affairs Medical Center, Durham, NC, USA. 2. Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA. 3. Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA. 4. Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. 5. Urology Section, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA. 6. Department of Urology, UCLA School of Medicine, Los Angeles, CA, USA. 7. Urology Section, Veterans Affairs Medical Center, Augusta, GA, USA. 8. Section of Urology, Department of Surgery, Augusta University, Augusta, GA, USA. 9. Department of Urology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. 10. Urology Section, Veterans Affairs Medical Center, San Francisco, CA, USA. 11. Department of Urology, Oregon Health and Science University, Portland, OR, USA. 12. Urology Department, University of California San Diego Health System, San Diego, CA, USA.
Abstract
OBJECTIVES: To examine the association between body mass index (BMI) and aggressive biochemical recurrence (BCR) using the Shared Equal Access Regional Cancer Hospital (SEARCH) database. MATERIAL AND METHODS: We identified 4123 men with complete data treated by radical prostatectomy between 1988 and 2015. We tested the association between BMI and BCR using Cox models, and among men with BCR, prostate-specific antigen doubling time (PSADT) was compared across BMI categories using linear regression. Models were adjusted for age, race, prostate-specific antigen, biopsy Gleason score, clinical stage, year and surgical centre. RESULTS: Overall, 922 men (22%) were of normal weight (BMI <25 kg/m2 ), 1863 (45%) were overweight (BMI 25-29.9 kg/m2 ), 968 (24%) were obese (BMI 30-34.9 kg/m2 ), and 370 (9%) were moderately or severely obese (BMI ≥35 kg/m2 ). After adjustment for multiple clinical characteristics, higher BMI was significantly associated with higher risk of BCR (P = 0.008). Among men with BCR, men in the four BMI categories had similar multivariable-adjusted PSADT values (increasing BMI categories: 20.9 vs 21.3 vs 21.0 vs 14.9 months; P = 0.48). CONCLUSION: While we confirmed that higher BMI was associated with BCR, we found no link between BMI and PSADT at the time of recurrence. Our data suggest obese men do not have more aggressive recurrences. Future studies are needed to test whether obesity predicts response to salvage therapies.
OBJECTIVES: To examine the association between body mass index (BMI) and aggressive biochemical recurrence (BCR) using the Shared Equal Access Regional Cancer Hospital (SEARCH) database. MATERIAL AND METHODS: We identified 4123 men with complete data treated by radical prostatectomy between 1988 and 2015. We tested the association between BMI and BCR using Cox models, and among men with BCR, prostate-specific antigen doubling time (PSADT) was compared across BMI categories using linear regression. Models were adjusted for age, race, prostate-specific antigen, biopsy Gleason score, clinical stage, year and surgical centre. RESULTS: Overall, 922 men (22%) were of normal weight (BMI <25 kg/m2 ), 1863 (45%) were overweight (BMI 25-29.9 kg/m2 ), 968 (24%) were obese (BMI 30-34.9 kg/m2 ), and 370 (9%) were moderately or severely obese (BMI ≥35 kg/m2 ). After adjustment for multiple clinical characteristics, higher BMI was significantly associated with higher risk of BCR (P = 0.008). Among men with BCR, men in the four BMI categories had similar multivariable-adjusted PSADT values (increasing BMI categories: 20.9 vs 21.3 vs 21.0 vs 14.9 months; P = 0.48). CONCLUSION: While we confirmed that higher BMI was associated with BCR, we found no link between BMI and PSADT at the time of recurrence. Our data suggest obesemen do not have more aggressive recurrences. Future studies are needed to test whether obesity predicts response to salvage therapies.
Authors: Katherine M Flegal; Deanna Kruszon-Moran; Margaret D Carroll; Cheryl D Fryar; Cynthia L Ogden Journal: JAMA Date: 2016-06-07 Impact factor: 56.272
Authors: H Wadhwa; M K Terris; W J Aronson; C J Kane; C L Amling; M R Cooperberg; S J Freedland; M R Abern Journal: Prostate Cancer Prostatic Dis Date: 2016-10-04 Impact factor: 5.554
Authors: Jason C Massengill; Leon Sun; Judd W Moul; Hongyu Wu; David G McLeod; Christopher Amling; Raymond Lance; John Foley; Wade Sexton; Leo Kusuda; Andrew Chung; Douglas Soderdahl; Timothy Donahue Journal: J Urol Date: 2003-05 Impact factor: 7.450
Authors: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin Journal: JAMA Date: 2005-07-27 Impact factor: 56.272
Authors: Sameer A Siddiqui; Brant A Inman; Shomik Sengupta; Jeffrey M Slezak; Eric J Bergstralh; Bradley C Leibovich; Horst Zincke; Michael L Blute Journal: Cancer Date: 2006-08-01 Impact factor: 6.860
Authors: Jacques Baillargeon; Brad H Pollock; Alan R Kristal; Patrick Bradshaw; Javier Hernandez; Joseph Basler; Betsy Higgins; Steve Lynch; Thomas Rozanski; Dean Troyer; Ian Thompson Journal: Cancer Date: 2005-03-01 Impact factor: 6.860
Authors: Christopher L Amling; Robert H Riffenburgh; Leon Sun; Judd W Moul; Raymond S Lance; Leo Kusuda; Wade J Sexton; Douglas W Soderdahl; Timothy F Donahue; John P Foley; Andrew K Chung; David G McLeod Journal: J Clin Oncol Date: 2003-12-22 Impact factor: 44.544
Authors: Anthony V D'Amico; Judd W Moul; Peter R Carroll; Leon Sun; Deborah Lubeck; Ming-Hui Chen Journal: J Natl Cancer Inst Date: 2003-09-17 Impact factor: 13.506
Authors: June M Chan; Stacey A Kenfield; Rebecca E Graff; Crystal S Langlais; Erin L Van Blarigan; Claire H Pernar; Meir J Stampfer; Edward L Giovannucci; Lorelei A Mucci Journal: Br J Cancer Date: 2022-08-26 Impact factor: 9.075
Authors: Crystal S Langlais; Rebecca E Graff; Erin L Van Blarigan; Nynikka R Palmer; Samuel L Washington; June M Chan; Stacey A Kenfield Journal: Curr Oncol Rep Date: 2021-03-10 Impact factor: 5.075